TROY (TNFRSF19) is overexpressed in advanced glial tumors and promotes glioblastoma cell invasion via Pyk2-Rac1 signaling

Molecular Cancer Research

Volumn 8, Issue 11, 2010, Pages 1558-1567

  Paulino, Vincent M ^a   Yang, Zhongbo ^b   Kloss, Jean ^b   Ennis, Matthew J ^a   Armstrong, Brock A ^a   Loftus, Joseph C ^b   Tran, Nhan L ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE 2; MESSENGER RNA; RAC1 PROTEIN; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; BRAIN CORTEX; CANCER GRADING; CANCER INVASION; CELL DIFFERENTIATION; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; OVERALL SURVIVAL; PRIORITY JOURNAL; RNA INTERFERENCE; THALAMUS; TROY GENE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; FOCAL ADHESION KINASE 2; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMMUNOPRECIPITATION; NEOPLASM INVASIVENESS; RAC1 GTP-BINDING PROTEIN; RATS; RATS, WISTAR; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 78649640148     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-10-0334     Document Type: Article

References (59)

1. 2007-2008 Primary Brain Tumors in the United States Statistical Report. Chicago (IL): Central Brain Tumor Registry of the United States; 2008, p. 1.
2. Berens ME, Giese A. "...those left behind." Biology and oncology of invasive glioma cells. Neoplasia 1999;1:208-19.
3. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003;21:1624-36.
4. Teodorczyk M, Martin-Villalba A. Sensing invasion: cell surface receptors driving spreading of glioblastoma. J Cell Physiol 2010;222:1-10.
5. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment.Genes Dev 2007;21:2683-710.
6. Paulus W, Baur I, Beutler AS, Reeves SA. Diffuse brain invasion of glioma cells requires β1 integrins. Lab Invest 1996;75:819-26.
7. Uhm JH, Gladson CL, Rao JS. The role of integrins in the malignant phenotype of gliomas. Front Biosci 1999;4:D188-99.
8. Bao S, Wu Q, Li Z, et al. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res 2008;68:6043-8.
9. Le Mercier M, Fortin S, Mathieu V, Kiss R, Lefranc F. Galectins and gliomas. Brain Pathol 2010;20:17-27.
10. Le Mercier M, Fortin S, Mathieu V, et al. Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia 2009;11:485-96.
11. Camby I, Belot N, Lefranc F, et al. Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J Neuropathol Exp Neurol 2002;61:585-96.
12. Jung TY, Jung S, Ryu HH, et al. Role of galectin-1 in migration and invasion of human glioblastoma multiforme cell lines. J Neurosurg 2008;109:273-84.
13. Strik HM, Schmidt K, Lingor P, et al. Galectin-1 expression in human glioma cells: modulation by ionizing radiation and effects on tumor cell proliferation and migration. Oncol Rep 2007;18:483-8.
14. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
15. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005;23:2411-22.
16. Lefranc F, Facchini V, Kiss R. Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist 2007;12:1395-403.
17. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104:487-501.
18. Mariani L, Beaudry C, McDonough WS, et al. Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation genes: a cDNA microarray analysis. J Neurooncol 2001;53:161-76.
19. Hoelzinger DB, Mariani L, Weis J, et al. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 2005;7:7-16. (Pubitemid 40209466)
20. Tran NL, McDonough WS, Donohue PJ, et al. The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol 2003;162:1313-21.
21. Tran NL, McDonough WS, Savitch BA, et al. Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-κB and correlate with poor patient outcome. Cancer Res 2006;66:9535-42.
22. Tran NL, McDonough WS, Savitch BA, Sawyer TF, Winkles JA, Berens ME. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFκB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 2005;280:3483-92.
23. Hu S, Tamada K, Ni J, Vincenz C, Chen L. Characterization of TNFRSF19, a novel member of the tumor necrosis factor receptor superfamily. Genomics 1999;62:103-7.
24. Park JB, Yiu G, Kaneko S, et al. A TNF receptor family member, TROY, is a coreceptor with Nogo receptor in mediating the inhibitory activity of myelin inhibitors. Neuron 2005;45:345-51.
25. Pispa J, Mikkola ML, Mustonen T, Thesleff I. Ectodysplasin, Edar and TNFRSF19 are expressed in complementary and overlapping patterns during mouse embryogenesis. Gene Expr Patterns 2003;3:675-9.
26. Hisaoka T, Morikawa Y, Kitamura T, Senba E. Expression of a member of tumor necrosis factor receptor superfamily, TROY, in the developing mouse brain. Brain Res Dev Brain Res 2003;143:105-9.
27. Hisaoka T, Morikawa Y, Kitamura T, Senba E. Expression of a member of tumor necrosis factor receptor superfamily, TROY, in the developing olfactory system. Glia 2004;45:313-24.
28. Shao Z, Browning JL, Lee X, et al. TAJ/TROY, an orphan TNF receptor family member, binds Nogo-66 receptor 1 and regulates axonal regeneration. Neuron 2005;45:353-9.
29. Eby MT, Jasmin A, Kumar A, Sharma K, Chaudhary PM. TAJ, a novel member of the tumor necrosis factor receptor family, activates the c-Jun N-terminal kinase pathway and mediates caspase-independent cell death. J Biol Chem 2000;275:15336-42.
30. Qiu W, Hu Y, Andersen TE, et al. Tumor necrosis factor receptor superfamily member 19 (TNFRSF19) regulates differentiation fate of human mesenchymal (stromal) stem cells through canonical Wnt signaling and C/EBP. J Biol Chem 2010;285:14438-49.
31. Nakada M, Drake KL, Nakada S, Niska JA, Berens ME. Ephrin-B3 ligand promotes glioma invasion through activation of Rac1. Cancer Res 2006;66:8492-500. (Pubitemid 44449162)
32. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215-25, discussion 26-9.
33. Loftus JC, Yang Z, Tran NL, et al. The Pyk2 FERM domain as a target to inhibit glioma migration. Mol Cancer Ther 2009;8:1505-14.
34. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998;95:2509-14.
35. Chuang YY, Tran NL, Rusk N, Nakada M, Berens ME, Symons M. Role of synaptojanin 2 in glioma cell migration and invasion. Cancer Res 2004;64:8271-5.
36. Lipinski CA, Tran NL, Menashi E, et al. The tyrosine kinase pyk2 promotes migration and invasion of glioma cells. Neoplasia 2005;7:435-45.
37. Lipinski CA, Tran NL, Viso C, et al. Extended survival of Pyk2 or FAK deficient orthotopic glioma xenografts. J Neurooncol 2008;90:181-9.
38. Salhia B, Tran NL, Chan A, et al. The guanine nucleotide exchange factors trio, Ect2, and Vav3 mediate the invasive behavior of glioblastoma. Am J Pathol 2008;173:1828-38.
39. Spanjaard RA, Whren KM, Graves C, Bhawan J. Tumor necrosis factor receptor superfamily member TROY is a novel melanoma biomarker and potential therapeutic target. Int J Cancer 2007;120:1304-10.
40. Weaver KD, Yeyeodu S, Cusack JC, Jr., Baldwin AS, Jr., Ewend MG. Potentiation of chemotherapeutic agents following antagonism of nuclear factor κ B in human gliomas. J Neurooncol 2003;61:187-96.
41. Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005;5:297-309.
42. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999;18:6853-66.
43. Kojima T, Morikawa Y, Copeland NG, et al. TROY, a newly identified member of the tumor necrosis factor receptor superfamily, exhibits a homology with edar and is expressed in embryonic skin and hair follicles. J Biol Chem 2000;275:20742-7.
44. Hashimoto T, Schlessinger D, Cui CY. Troy binding to lymphotoxin-α activates NFκB mediated transcription. Cell Cycle 2008;7:106-11.
45. Johnston AL, Lun X, Rahn JJ, et al. The p75 neurotrophin receptor is a central regulator of glioma invasion. PLoS Biol 2007;5:e212.
46. Wang L, Rahn JJ, Lun X, et al. γ-Secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor. PLoS Biol 2008;6:e289.
47. Girault JA, Costa A, Derkinderen P, Studler JM, Toutant M. FAK and PYK2/CAKβ in the nervous system: a link between neuronal activity, plasticity and survival? Trends Neurosci 1999;22:257-63.
48. Avraham H, Park SY, Schinkmann K, Avraham S. RAFTK/Pyk2-mediated cellular signalling. Cell Signal 2000;12:123-33.
49. Gutenberg A, Bruck W, Buchfelder M, Ludwig HC. Expression of tyrosine kinases FAK and Pyk2 in 331 human astrocytomas. Acta Neuropathol (Berl) 2004;108:224-30.
50. van der Horst EH, Weber I, Ullrich A. Tyrosine phosphorylation of PYK2 mediates heregulin-induced glioma invasion: novel heregulin/HER3-stimulated signaling pathway in glioma. Int J Cancer 2005;113:689-98.
51. Lipinski CA, Tran NL, Bay C, et al. Differential role of proline-rich tyrosine kinase 2 and focal adhesion kinase in determining glioblastoma migration and proliferation. Mol Cancer Res 2003;1:323-32.
52. Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer 1999;81:682-7.
53. Gomez del Pulgar T, Benitah SA, Valeron PF, Espina C, Lacal JC. Rho GTPase expression in tumourigenesis: evidence for a significant link. BioEssays 2005;27:602-13.
54. Chan AY, Coniglio SJ, Chuang YY, et al. Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion. Oncogene 2005;24:7821-9.
55. Tanabe K, Bonilla I, Winkles JA, Strittmatter SM. Fibroblast growth factor-inducible-14 is induced in axotomized neurons and promotes neurite outgrowth. J Neurosci 2003;23:9675-86.
56. Ruan W, Lee CT, Desbarats J. A novel juxtamembrane domain in tumor necrosis factor receptor superfamily molecules activates Rac1 and controls neurite growth. Mol Biol Cell 2008;19:3192-202.
57. Jarzynka MJ, Hu B, Hui KM, et al. ELMO1 and Dock180, a bipartite Rac1 guanine nucleotide exchange factor, promote human glioma cell invasion. Cancer Res 2007;67:7203-11.
58. Gao C, Blystone SD. A Pyk2-Vav1 complex is recruited to β3-adhesion sites to initiate Rho activation. Biochem J 2009;420:49-56.
59. Gakidis MA, Cullere X, Olson T, et al. Vav GEFs are required for β2 integrin-dependent functions of neutrophils. J Cell Biol 2004;166: 273-82.